Repurposing Annita® drug against ZIKV infection on Human Placenta and Cervix cells

Abstract

Introduction: Drug repurposing is the promptest way to obtain an effective drug during a global public health emergency as the spread of Zika virus that is associated with the congenital syndrome. Why the virus reaches the fetus is still unclear, however the placenta represents an important route of transmission, since the virus was detected in vivo and in vitro human and murine placenta. The fetal infection may occur by passing the virus through spaces created by lesions or inflammation that may break the placental barrier. Another hypothesis is that the virus crosses the placenta through infection of host cells, being possible the transmission of ZIKV to the fetus occur from sexual transmission. Despite the emerging severity caused by the ZIKV infection, there still no specific treatment for this disease. The antiparasitic and antiviral drug Annita® already approved through the Food and Drug Admistration and safe for pediatric use and for administration in pregnant women, being included in category B, could have activity against ZIKV due to broad aspect and affordable price.